

8th Annual Congress on Analytical and Bioanalytical Techniques & 14th International Conference and Exhibition on Pharmaceutical Formulations

August 28-30, 2017 Brussels, Belgium

Resonant X-ray emission spectroscopy for analysis of platinum anti-cancer complexes and their interaction with biomolecules

Joanna Czapla-Masztafiak¹, Jacinto Sá², Jakub Szlachetko³ and Wojciech M Kwiatek¹

¹Institute of Nuclear Physics Polish Academy of Sciences, Poland


²Uppsala University, Sweden

³Institute of Physics, Jan Kochanowski University Kielce, Poland

Statement of the Problem: The accidental discovery of the anticancer properties of cisplatin and its clinical introduction in the 1970s paved the way for the use of platinum based metalodrugs in chemotherapy. Second-generation analogues (e.g. carboplatin) were discovered shortly after. However, the clinical introduction of new anticancer metalodrugs has slowed down dramatically, especially considering the number of new drugs synthesized each year. Probably, the most critical factor for this slow progress is the inability to elucidate in a timely manner how metalodrugs induce tumor death, precluding the rational development of new derivatives with enhanced anticancer capabilities. Most chemotherapeutic agents exert their antitumor effect by damaging DNA and its replication machinery. Therefore, the correlation between the covalent bonding to DNA and the cytotoxicity of the metal complex remains a central step in the search for new anticancer drugs.

Methodology & Theoretical Orientation: Herein, we report a strategy to follow the chemical structure and coordination of platinum-based antitumor drugs by DNA under physiological conditions, namely by means of *in situ* resonant X-ray emission spectroscopy (RXES). RXES is an atom specific photon-in photon-out scattering technique which avoids the tedious steps of extraction and crystallization required by conventional X-ray techniques.

Conclusion & Significance: The spectroscopic method proposed by us was successfully used to validate the mechanism of action of cisplatin as well as elucidate the DNA binding of Pt103 compound that exhibits cytotoxic activity. Moreover, we showed that RXES can be used to unveil the electronic structure of metalodrugs with high resolution and sensitivity and to disentangle differences in the electronic structure of the metal center induced by a secondary ligand stereochemistry.



Biography

Joanna Czapla-Masztafiak has her expertise in the use of X-ray spectroscopy to study biological systems. She obtained Master's Degree in Medical Physics from AGH University of Science and Technology in Krakow, Poland and PhD in Physical Sciences from Institute of Nuclear Physics Polish Academy of Sciences in Krakow, Poland. She also successfully completed Postdoc project in Paul Scherrer Institute in Villigen, Switzerland. Her research interests cover the application of X-ray spectroscopy to study DNA damage caused by radiation and chemical agents. Recently, she is developing laboratory instrument for X-ray absorption and X-ray emission studies of the interaction of metal compounds with biomolecules.

joanna.czapla@ifj.edu.pl